乙磺硝唑（SR - 2508）在膀胱癌和宫颈癌中的药代动力学：来自尿液扩散的证据。
Pharmacokinetics of etanidazole (SR-2508) in bladder and cervical cancer: evidence of diffusion from urine.
作者信息
Awwad H K, el Badawy S, abd el Baki H, Zaghloul M, el Moneim Osman A, Akoush H, Fairchild K
机构信息
Radiotherapy Department, National Cancer Institute, Cairo, Egypt.
出版信息
Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):1083-4. doi: 10.1016/0360-3016(89)90921-8.
Following an IV infusion of 2.0 g/m2 of Etanidazole, the mean tumor concentration 40 min after injection was 126 micrograms/g in bladder cancer and 65 micrograms/g in cervical cancer. The tumor/plasma concentration ratio was 1.88 in bladder and 0.85 in cervical cancer. This high tumor concentration in bladder cancer could be accounted for by diffusion from a highly concentrated urine. This renders bladder cancer a suitable clinical model for testing this sensitizer.
静脉输注2.0 g/m²的依他硝唑后，注射后40分钟膀胱癌的平均肿瘤浓度为126微克/克，宫颈癌为65微克/克。膀胱癌的肿瘤/血浆浓度比为1.88，宫颈癌为0.85。膀胱癌中这种高肿瘤浓度可能是由于从高浓度尿液中扩散所致。这使得膀胱癌成为测试这种增敏剂的合适临床模型。
Zotero 插件